ASLAN Pharmaceuticals nets $34 mln Series C

Singapore-based biotech company ASLAN Pharmaceuticals has raised $34 million in Series C funding. Accuron Technologies Limited, a Temasek Holdings subsidiary, led the round. Other investors included Tianda Pharmaceuticals Limited, Haitong International, Morningside, Bioveda, Cenova and Sagamore Bioventures.

North AmericaUSBriefs